Drugs / ChAdOx1-HPV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04607850 | Mar 2021 → Jan 2024 | cervical intraepithelial neoplasia, human papilloma virus infection | Barinthus Biotherapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1-HPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04607850 ↗ |
| Modality | Vaccine | “ChAdOx1)-Vectored Multigenotype High Risk Human Papillomavirus (hrHPV) Vaccine” NCT04607850 ↗ |